Table 1. Clinical characteristics.
| Subtypes | Total | AO, IDH mt-LOH | AA, IDH mt | AG, IDH wt | AG, NOS a | Glioblastoma, IDH mt | Glioblastoma, IDH wt | Glioblastoma, NOS |
| Number | 109 | 7 | 5 | 10 | 37 | 3 | 19 | 28 |
| Age at first MRI examination (years) | ||||||||
| Median (IQR) | 48 (35-57) | 35 (31.8-44.5) | 39 (25.8-62.8) | 45.50 (33-60) | 48 (33.5-56.3) | 49 (41.5-52) | 53 (47.3-58) | 47 (36.5-57.5) |
| Gender (Female) | 43 (39.5%) | 4 (57.1%) | 1 (20%) | 3 (30%) | 18 (48.7%) | 2 (66.7%) | 8 (42.1%) | 7 (25%) |
| Cortisol therapy | 7 (6.4%) | 0 (0) | 0 (0) | 1 (10%) | 2 (5.4%) | 0 (0) | 2 (10.5%) | 2 (7.1%) |
| Contrast-enhancement (CE) type at first MRI examination | ||||||||
| Complete enhanced | 34 (31.2%) | 1 (14.3%) | 1 (20%) | 1 (10%) | 7 (18.9%) | 1 (33.3%) | 14 (73.7%) | 8 (28.6%) |
| Incomplete enhanced | 20 (18.4%) | 1 (14.3%) | 2 (40%) | 2 (20%) | 7 (18.9%) | 0 (0) | 2 (10.5%) | 8 (28.6%) |
| Unknown b | 55 (50.5%) | 5 (71.4%) | 2 (40%) | 8 (80%) | 23 (62.2%) | 2 (66.7%) | 3 (15.8%) | 12 (42.9%) |
| Number of lobes involved | ||||||||
| Median (IQR) | 1 (1-2) | 1 (1-2) | 1 (0.8-3) | 1 (0-2) | 1 (1-2) | 1 (1-1.8) | 1 (1-2) | 1 (1-2) |
| Bilateral | 8 (7.3%) | 0 (0) | 0 (0) | 1 (10%) | 5 (13.5%) | 0 (0) | 2 (10.5%) | 0 (0) |
| Tumor-edema interface | ||||||||
| Blur | 53 (48.6%) | 6 (85.7%) | 4 (80%) | 5 (50%) | 20 (54.1%) | 2 (66.67%) | 5 (26.3%) | 11 (39.3%) |
| Initial mean tumor diameter (iMTD, mm) | ||||||||
| Median (IQR) | 38.6 (30-47.4) | 31.4 (30.4-44.7) | 36.8 (28.9-44.9) | 34.05 (28.6-39.4) | 41 (32.1-51.1) | 40.4 (39.5-60.5) | 36.1 (29.7-42.6) | 37.6 (28.5-52.1) |
| Interval time between first and last preoperative MRI examinations (days) | ||||||||
| Median (IQR) | 41 (22.7-114.8) | 326.4 (132.8-1492.5) | 284.4 (176.8-383.5) | 29.09 (17.2-37.8) | 34.0 (18.8-66) | 15.8 (14.5-733) | 37.7 (28.6-185.4) | 45 (25.5-81.5) |
| Numbers of MRI examinations | ||||||||
| Median (IQR) | 2 (2-2) | 2 (2-5.5) | 2 (2-3.3) | 2 (2-3) | 2 (2-2) | 2 (2-2) | 2 (2-2) | 2 (2-2) |
Abbreviations: LOH, 1p/19q loss of heterozygosity; NOS, not otherwise specified; wt, wild type; mt, mutation type; AO, anaplastic oligodendroglioma; AA, anaplastic astrocytoma; AG, Anaplastic glioma; IQR, interquartile range.
a. Three patients were oligoastrocytoma, IDH mutation and 1p/19q NOS.
b. High grade gliomas with single CE-T1WI at pre-surgery MRI examination.